Protalix BioTherapeutics, Inc.
PLX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLX
Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases using its proprietary ProCellEx plant cell-based expression system, with approved products Elfabrio and Elelyso and a pipeline including PRX-115 for uncontrolled gout.
Key risk: Elfabrio commercial risks
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Protalix BioTherapeutics, Inc..
Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases using its proprietary ProCellEx plant cell-based expression system, with approved products Elfabrio and Elelyso and a pipeline including PRX-115 for uncontrolled gout.
- Protalix has two approved products: Elfabrio (pegunigalsidase alfa) for Fabry disease and Elelyso for Gaucher disease, with commercial support from partners Pfizer and Chiesi [sec_mda · as of 2026-08-12].
- The company is advancing its pipeline, including PRX-115 (pegylated Uricase) for uncontrolled gout, which has completed Phase I, and PRX-119 (long-acting DNase I) in preclinical stages [sec_mda · as of 2026-03-18].
- As of June 30, 2026, Protalix reported cash and equivalents of $27.4M, total revenue of $19.9M, and net income of $3.8M [sec].
- The company shifted its focus in the second half of 2023 from clinical development of pegunigalsidase alfa to supporting its commercial launch and strengthening its pipeline [sec · filed 2025-04-30].
- Protalix expects to continue incurring significant R&D expenditures and may need additional financing, as revenues from Elfabrio and Elelyso may not be sufficient to fund all costs [sec_mda · as of 2026-08-12].
What works
- Protalix has two FDA-approved products generating revenue, Elfabrio and Elelyso, providing a commercial foundation [sec_mda · as of 2026-08-12].
- The company's proprietary ProCellEx platform enables development of protein-based therapies for rare diseases, with potential for multiple product candidates [sec_mda · as of 2026-05-13].
- Protalix reported net income of $3.8M for the six months ended June 30, 2026, indicating a period of profitability [sec].
What to weigh
- Protalix faces risks related to Elfabrio's market acceptance, competition, and a boxed warning from the FDA [sec_mda · as of 2025-11-13].
- The company expects significant future R&D expenditures and may need additional financing, which could be challenging given stock price volatility [sec_mda · as of 2026-08-12].
- Revenues from Elfabrio and Elelyso may not be sufficient to fund all planned expenditures, creating potential cash flow pressure [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Protalix has two approved products and commercial partnerships.
“risks relating to our ability to manage our relationship with our collaborators, distributors, and partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi”
SEC MD&A · August 12, 2026
The company shifted focus to commercial support and pipeline development in 2023.
“During the second half of fiscal year 2023 through fiscal year 2024, we shifted our focus to the support of our commercial partner's launch efforts post approval, and redirecting our R&D and clinical resources towards the strengthening of our pipeline of product candidates”
SEC filings · April 30, 2025
PRX-115 is a lead pipeline candidate for uncontrolled gout.
“our leading drug candidate, PRX-115 (pegylated Uricase for the potential treatment of uncontrolled Gout)”
SEC filings · April 30, 2025
Protalix expects significant future expenditures and potential financing needs.
“As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures.”
SEC MD&A · August 12, 2026
Risks & what to watch (3)›
Key risks
- Elfabrio commercial risks — Market acceptance, competition, and FDA boxed warning could limit Elfabrio sales [sec_mda · as of 2025-11-13].
- Financing and cash runway — Revenues may not cover R&D costs; additional financing may be needed but is uncertain [sec_mda · as of 2026-08-12].
- Clinical trial risks — Results may not support safety or efficacy claims for pipeline candidates [sec_mda · as of 2025-11-13].
What to watch
- Completion of enrollment in the RELEASE study for PRX-115 [sec_mda · as of 2026-03-18].
- Progress of PRX-119 (long-acting DNase I) through IND-enabling studies [sec_mda · as of 2026-03-18].
- Revenue trends from Elfabrio and Elelyso and their sufficiency to fund operations [sec_mda · as of 2026-08-12].
- Potential need for additional financing or strategic partnerships [sec_mda · as of 2026-08-12].
Sources: SEC filings · SEC MD&A · Generated August 13, 2026 · How we verify sources →
Run Protalix BioTherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Protalix BioTherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
13.5 months
D/E 0.55 · 3% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$35.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,616,962 | $7.8M |
| mak capital one llc | 3,544,139 | $7.7M |
| renaissance technologies llc | 1,224,800 | $2.7M |
| state street corp | 972,815 | $2.1M |
| northern trust corp | 885,448 | $1.9M |
| geode capital management, llc | 865,298 | $1.9M |
| stratos wealth partners, ltd. | 500,000 | $1.1M |
| vanguard portfolio management llc | 432,485 | $938K |
| prospera financial services inc | 418,570 | $908K |
| morgan stanley | 301,793 | $655K |
Showing top 10 of 99 institutional holders of Protalix BioTherapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 29, 2026- % of float
- 6.1%
- Days to cover
- 4.8
- Shares short
- 4,726,273
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Protalix BioTherapeutics, Inc.?
Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases using its proprietary ProCellEx plant cell-based expression system, with approved products Elfabrio and Elelyso and a pipeline including PRX-115 for uncontrolled gout.
What is Protalix BioTherapeutics, Inc.'s lead drug candidate?
Protalix BioTherapeutics, Inc.'s most advanced tracked candidate is elelyso (Approved) for Gaucher disease.
Who is the CEO of Protalix BioTherapeutics, Inc.?
Mr. Dror Bashan is the chief executive officer of Protalix BioTherapeutics, Inc. (PLX).
Where is Protalix BioTherapeutics, Inc. headquartered?
Protalix BioTherapeutics, Inc. (PLX) is headquartered in Hackensack, NJ, United States.
What therapeutic areas does Protalix BioTherapeutics, Inc. focus on?
Protalix BioTherapeutics, Inc. develops therapies across Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.